Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Statement of the Problem: Due to its unique composition, human milk is an excellent source of nutrients and also many
bioactive ingredients, which have as a potential healthy effect. Oligosaccharides (HMOs, Human Milk Oligosaccharides) is the
main group with potential biocidal using, especially of medical procedures. Due to the concentration of the components of
human milk, oligosaccharides, in addition to lactose and fats, are the third component. Due to their bioactivity, we hypothesised
that HMOs exhibit an antimicrobial activity against a wide spectrum of human pathogenic bacteria. A systematic investigation
of the antimicrobial spectrum of polled or individual HMOs has not been performed for bacterial biofilm structure.
Methodology & Theoretical Orientation: Clinical isolates and reference strains of Escherichia coli, Pseudomonas aeruginosa,
Klebsiella pneumoniae, MRSA, Burkholderia cepacia and Acinetobacter baumanii were used in this study. Human milk was
obtained from nine healthy donors from Human Milk Bank in Warsaw Poland. Milk samples were pooled, next in the skimming
milk proteins were precipitated. Carbohydrates with oligosaccharides fraction were then lyophilized. In the quantitative
analysis of the biofilm we done determination of the minimal biofilm inhibitory concentration (MBIC), determination of
colony forming units in the planktonic phase and of the minimal biofilm eradicated concentration (MBEC). Live/dead staining
of the biofilms and CLSM image acquisition were used.
Conclusion & Significance: In our preliminary work, we could show that the human milk saccharide fraction exhibit
moderately activity against some planktonic bacteria species (e.g. clinical isolates of P. aeruginosa and MRSA) and inhibit
biofilm formation of P. aeruginosa. HMOs showed a biofilm eradicating effect on most tested pathogens. Oligosaccharides may
potentially constitute a new medicinal product of natural origin, used in the prophylaxis and treatment of respiratory tract
infections in patients with cystic fibrosis and COPD.
Recent Publications:
1. Ackerman, D. L., et al. (2017). Human Milk Oligosaccharides Exhibit Antimicrobial and Antibiofilm Properties
against Group B Streptococcus. ACS Infect Dis 3(8): 595-605.
2. Bode, L. (2015). The functional biology of human milk oligosaccharides. Early Hum Dev 91(11): 619-622.
3. Cosgrove, S. E., et al. (2002). Health and economic outcomes of the emergence of third-generation cephalosporin
resistance in Enterobacter species. Arch Intern Med 162(2): 185-190.
4. Lewis, K. (2001). Riddle of biofilm resistance. Antimicrob Agents Chemother 45(4): 999-1007.
5. LiPuma, J. J. (2005). Update on the Burkholderia cepacia complex. Curr Opin Pulm Med 11(6): 528-533.
Biography
Sylwia Jarzynka, together with a team of scientists from the Medical Biology Department in cooperation with the Jena University Hospital, Center for Infectious Diseases and Infection Control are involved in the study of antimicrobial biotic and abiotic factors. Special achievements of the researchers concern the inhibition of bacterial biofilm with the use of equal biomaterials, which are potential carriers of antimicrobial agents.